Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
5650studies shown
Showing 3,865-3,876 of 5,650
Drug study icon
RecruitingNCT07029581

ACP-204 for Schizophrenia

This study is recruiting in the United States, in France, in Bulgaria, .... It is testing ACP-204 for Schizophrenia.

Multiple locations, including Irvine
SchizophreniaDrugA study involving a medication or substance.From 55 Years to 84 Years
Countries
United States, France, Bulgaria, ...
Sponsor
ACADIA Pharmaceuticals Inc.
Condition
Schizophrenia
Drug study icon
RecruitingISRCTN97049967

Effectiveness of lurasidone in schizophrenia

This study is recruiting in the United Kingdom, in Argentina, in Brazil, .... It is testing lurasidone for schizophrenia.

In United Kingdom
SchizophreniaOtherFrom 18 Years to 75 Years
Countries
United Kingdom, Argentina, Brazil, ...
Sponsor
Dainippon Sumitomo Pharma America Inc. (USA)
Condition
Schizophrenia
Drug study icon
RecruitingNCT06559306

Treatment With Seltorexant for depression

This study is recruiting in the United States, in Argentina, in Brazil, .... It is testing treatment With Seltorexant for depression.

Multiple locations, including Birmingham
DepressionDrugFrom 18 Years to 74 Years
Countries
United States, Argentina, Brazil, ...
Sponsor
Janssen Research & Development, LLC
Condition
Depression
Drug study icon
RecruitingISRCTN42835524

Phase I Single- and Multiple-Ascending Dose study of EVX-101

This study is testing a medication approach for people with Depression or Mental and Behavioural Disorders. Participants receive a study treatment and complete follow-up visits and assessments.

In United Kingdom
DepressionOtherOver 18 Years
Countries
United Kingdom
Sponsor
Evecxia Therapeutics Inc.
Condition
Depression
Drug study icon
RecruitingISRCTN77277298

Hypericum extract WS® 5570 for depression

This study is recruiting in Germany. It is testing Hypericum extract WS® 5570 for depression.

In Germany
DepressionOtherOver 18 Years
Countries
Germany
Sponsor
Schwabe Pharmaceuticals (Germany)
Condition
Depression
Drug study icon
RecruitingISRCTN13032035

Phase III study to prove the efficacy, safety and tolerability of Silexan® in people with anxiety disorder

This study is looking at whether Silexan® 80 mg (1 capsule) per day or placebo orally for 10 weeks can help people with anxiety not otherwise specified, Mental and Behavioural Disorders, or Other anxiety. Participants receive a study treatment and complete follow-up visits and assessments.

In Germany
AnxietyOtherOver 18 Years
Countries
Germany
Sponsor
Dr. Willmar Schwabe GmbH & Co. KG (Germany)
Condition
Anxiety
Device study icon
RecruitingNCT07544563

Phenotypic Exploration During Sensory Stimulation in an Acoustic Chamber

This study exists to learn from real-world information that can show how this type of care fits into care. For people living with Anxiety, that matters because care needs to work in daily life, not just in theory.

In Paris
Anxiety, DepressionOtherOver 18 Years
Countries
France
Sponsor
Centre Hospitalier St Anne
Condition
Anxiety, Depression
Other study type icon
RecruitingISRCTN17586238

Phone Pal: volunteering via smart-phone for people with psychosis

This study is looking at whether a digital support tool can help people with Psychosis or Mental and Behavioural Disorders. Participants take part in a digital support tool and complete follow-up assessments.

In United Kingdom
SchizophreniaOtherFrom 18 Years to 120 Years
Countries
United Kingdom
Sponsor
Queen Mary University of London
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.